Clinical Trials Logo

Lobular Carcinoma in Situ clinical trials

View clinical trials related to Lobular Carcinoma in Situ.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT02928978 Recruiting - Clinical trials for Ductal Carcinoma In Situ

Ruxolitinib for Premalignant Breast Disease

TBCRC042
Start date: May 13, 2018
Phase: Phase 2
Study type: Interventional

This study is evaluating how ruxolitinib affects premalignant breast cells. One half of the study participants will receive ruxolitinib for approximately 15 days, and the other half will receive a placebo (sugar pill) for approximately 15 days. Once study participants have completed their ruxolitinib or placebo, participants will undergo surgery to remove the premalignant breast tissue.